In:
International Journal of Cancer, Wiley, Vol. 136, No. 5 ( 2015-03)
Kurzfassung:
What's new? Within 18 months of completing initial chemotherapy, as many as 75% of women with epithelial ovarian cancer (EOC) experience relapse with chemoresistant disease. This phenomenon may be overcome through the discovery of new therapies that are capable of restoring drug sensitivity in resistant cells. Two such agents include the multikinase inhibitor dorsomorphin and its analog LDN‐193189, which are reported here to increase survival in a mouse xenograft model of EOC. The agents successfully resensitized drug‐resistant ovarian cancer cells to the killing effects of platinum agents. Mechanistic evaluation revealed that dorsomorphin typically induces autophagy, whereas LDN‐193189 induces apoptosis.
Materialart:
Online-Ressource
ISSN:
0020-7136
,
1097-0215
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2015
ZDB Id:
218257-9
ZDB Id:
1474822-8